1．国家自然科学基金，青年项目，Myo9b在恶性胸腔积液发生机制中的作用，2018.01-2020.12，24，主持

2．北京市自然科学基金，面上项目，巨噬细胞源补体C1q在恶性胸腔积液中的免疫调节作用，2023.01-2025.12，20，主持

3．国家自然科学基金，重大项目，结核分枝杆菌与宿主互作的蛋白鉴定及作用机制，2024.01-2028.12，87.5，骨干

4．北京市医院管理中心，“青苗”人才培养计划，2023.01-2024.12，14，主持

5．北京市呼吸疾病研究所，北京市卫健委改革与发展项目（3项），肌球蛋白9b影响巨噬细胞抗原提呈在恶性胸腔积液中的作用，2021、2023、2024，30，主持

6．北京朝阳医院科技创新基金，联合实验室项目，肌球蛋白9b小分子抑制剂筛选及其对恶性胸腔积液的抑制作用，2022.09-2024.08，17，主持

期刊论文

(1) Yi, Feng-Shuang#, Qiao, Xin#, Dong,Shu-Feng, Chen, Qing-Yu, Wei, Rui-Qi, Shao, Ming-Ming*, Shi, Huan-Zhong*. ComplementC1q is a key player in tumor-associated macrophage-mediated CD8+ T cell and NKcell dysfunction in malignant pleural effusion. International Journal of Biological Sciences, 2024, 20(15), 5979-5998.

(2) Dong,Shu-Feng#; Shi, Xin-Yu; Wu, Xiu-Zhi*; Yi, Feng-Shuang*, IFN-γ InducesPleural Mesothelial Cells to Recruit Immune Cells via CXCL10-CXCR3 Axis in aMouse Pleurisy Model, Journal of Inflammation Research. 2025, 18:2521–2530.

(3) Yi, Feng-Shuang#; Zhang, Xin#; Zhai,Kan; Huang, Zhong-Yin; Wu, Xiu-Zhi; Wu, Min-Ting; Shi, Xin-Yu; Pei, Xue-Bin;Dong, Shu-Feng; Wang, Wen; Yang, Yuan; Du, Juan; Luo, Zeng-Tao; Shi,Huan-Zhong*; TSAd Plays a Major Role in Myo9b-Mediated Suppression of MalignantPleural Effusion by Regulating TH1/TH17 Cell Response, Journal of Immunology, 2020, 205(10)：2926-2935. （封面故事文章）

(4) Yi, Feng-Shuang; Zhai, Kan; Shi,Huan-Zhong*; Helper T cells in malignant pleural effusion, Cancer Letters, 2021, 500:21-28.

(5) Yi, Fengshuang#, Kong, Ruirui#, Ren,Jinqi#, Zhu, Li, Lou, Jizhong, Wu, Jane Y*, Feng, Wei*. NoncanonicalMyo9b-RhoGAP Accelerates RhoA GTP Hydrolysis by a Dual-Arginine-FingerMechanism, Journalof Molecular Biology,2016, 428(15):3043-3057.

(6) Kong, Ruirui#, Yi, Fengshuang#, Wen, Pushuai, Liu,Jianghong, Chen, Xiaoping, Ren, Jinqi, Li, Xiaofei, Shang, Yulong, Nie,Yongzhan, Wu, Kaichun, Fan, Daiming, Zhu, Li*, Feng, Wei*, Wu, Jane Y*. Myo9bis a key player in SLIT/ROBO-mediated lung tumor suppression, The Journal of ClinicalInvestigation, 2015, 125(12): 4407-4420.

(7) Yi, Fengshuang*; Zhang, Xin; LiangRuobing; Assembly of the Non-Canonical Myo9a-RhoGAP and RhoA·GDP TransitionState Complex in the Presence of MgF3-, The Protein Journal,2021, 40(6):842-848.

(8) Shi, Xin-Yu#; Yi, Feng-Shuang#; Wang, Zheng#; Qiao, Xin; Zhai, Kan*; Prognosticvalue of a new score using serum alkaline phosphatase and pleural effusionlactate dehydrogenase for patients with malignant pleural effusion, Thoracic Cancer, 2020, 11(2)：320-328.

(9) Shao, Ming-Ming;Qiao, Xin; Chen, Qing-Yu; Yi, Feng-Shuang*, A comprehensive study ofalternative splicing in malignant pleural mesothelioma identifies potentialtherapeutic targets in a new cluster with poor survival, Thoracic Cancer, 2022,13(16):2318-2330.

(10) Shao, Ming-Ming#*; Shi, Meier#; Du, Juan; Pei, Xue-Bin, Gu,Bei-Bei, Yi, Feng-Shuang*, Metabolic landscape of bronchoalveolar lavagefluid in Coronavirus Disease 2019 at single cell resolution, Frontiers inImmunology. 2022, 13:829760.

发明专利

施焕中；伊凤双；翟侃，与恶性胸腔积液相关的靶点MYO9B及其应用, 2021-12-28

施焕中；王雯；翟侃；伊凤双；吴秀芝，一种体外诱导初始B细胞分化为调节性B细胞的方法及其培养条件，2019-4-2

获得奖励

2022年首都医科大学科学技术奖三等奖，《胸腔积液免疫学及预后评价》，2023，伊凤双；邵明明；石欣雨